Alirocumab Plus Statin Lowers Cardiac Event Risk for Patients with Diabetes, ACS
The absolute risk reduction for patients with diabetes and recent ACS was 2.3% when on the PCSK9 inhibitor plus statin therapy.
Empagliflozin Reduces Renal Risks, Heart Failure Hospitalization in T2D Patients
Post-hoc analyses from the EMPA-REG OUTCOME study found consistent benefits for the therapy in comorbidities versus placebo.
Robert Gabbay, MD, PhD: The Role of Patient-Provider Communication in Medication Adherence
The chief medical officer of the Joslin Diabetes Center spoke about how providers communicate with their patients can affect their adherence to medications.
Insulin Degludec and Liraglutide Improves Add-on T2D Therapy in DUAL IX Trial
Xultophy was originally indicated as a therapy to improve glycemic control in adults with T2D mellitus that is inadequately controlled by basal insulin or liraglutide.
Improving Provider-Patient Communication in Cross-Cultural Scenarios
As physicians treat more diverse patient populations, the importance of communicating properly with patients can have resounding effects on outcomes and adherence.
Numbers Game: ADA, AHA Partner to Reduce Cardiovascular Disease Rates in T2D
Facing a major CVD prevalence in 30 million-plus patients with type 2 diabetes, the national agencies are planning a collaborative initiative that will last years.
PIONEER 1 Results Reveal Oral Semaglutide Significantly Reduced A1C
Both the intention-to-treat and on-treatment principles reported significant blood sugar reductions from the oral GLP-1 analogue.
Insulin Degludec Injection Improves A1C, Hypoglycemic Episodes in CONFIRM
The daily therapy was tested for T2D control benefits and treatment adherence versus insulin glargine U-300.
Semaglutide Shows Greater Weight Reduction Compared to Dulaglutide in SUSTAIN 7
More people achieved weight reduction of ≥5% and ≥10% with semaglutide in all BMI subgroups.
Eduardo Sanchez, MD, MPH: Addressing Cardiovascular Disease in Diabetes
The American Heart Association chief medical officer for prevention discussed the new ADA partnership and the new emphasis on comorbidity care.
Community Health Program Improves Diet, Depressive Symptoms Among Latina Mothers
The Healthy MOMs program resulted in positive improvements in diet and depressive symptoms for expecting Latinas, a population at a high risk for gestational and type 2 diabetes.
Canagliflozin Continues Showing of Positive Renal Outcomes in CANVAS Data
The Janssen product was found to be linked to a reduced risk of sustained kidney function loss, attenuated eFGR decline, and a reduction in albuminuria.
FDA OKs MiniMed 670G Automated Insulin Delivery Monitoring System in Pediatrics with Type 1 Diabetes
The expanded indication provides an important treatment option for clinicians and patients with type 1 diabetes.
Oral Semaglutide Improves T2D Glucose Levels, Body Weight Versus Competitors
The investigative GLP-1 receptor agonist was compared to liraglutide, sitagliptin, and placebo in adult patients with type 2 diabetes.
SGLT2 Inhibitors Associated with Lower Rates of Death, Hospitalization for Heart Failure in Patients with Type 2 Diabetes
Benefit was seen in 5 countries regardless of SGLT2 inhibitor used.
Single Dose of Glucagon Receptor Antibody Found to be as Effective in Reducing Insulin Need
Human antibody may substantially reduce need for insulin in patients with T1D.
Kausik Ray, MD, on the ODYSSEY Trial
Kausik Ray highlights the differences between the ODYSSEY DM-INSULIN trial differ from previous trials of PCSK9 inhibitors.
CANVAS Results Show Significant Benefits for Cardiovascular and Kidney Disease
Results have major worldwide implications for type 2 diabetes treatment.
DEVOTE Trial Demonstrates Cardiovascular Safety and Reduces Risk of Severe Hypoglycemia
New-generation insulin found to have comparable cardiovascular safety to insulin glargine and significantly reduce episodes of severe hypoglycemia.
Results from inTandem1 and inTandem2 Unveiled at ADA 77th Scientific Sessions
Two pivotal studies on sotagliflozin were presented at the ADA’s 77th Scientific Sessions.
LixiLan-L Phase 3 Study Results Presented at ADA 77th Scientific Sessions
Insulin glargine 100 Units/mL and lixisenatide 33 mcg/mL combined lowered A1C levels by 1.09% to 2.41% after 30 weeks.
REMOVAL Trial Results Presented at ADA 77th Scientific Sessions
Metformin may reduce the risk of heart disease in adults with T1D.
ODYSSEY DM-DYSLIPIDEMIA Results Presented at ADA 77th Scientific Sessions
ODYSSEY DM-DYSLIPIDEMIA is 1 of 2 studies on alirocumab presented at ADA Scientific Sessions.
ODYSSEY DM-INSULIN Results Presented at ADA 77th Scientific Sessions
ODYSSEY DM-INSULIN is 1 of 2 studies on alirocumab presented at ADA Scientific Sessions.
Investigational SGLT-2 Inhibitor Meets Primary Endpoint in Phase 3 Studies
Merck and Pfizer have announced that VERTIS MET and VERTIS SITA met primary endpoints.
DELIVER 3 Results Presented at ADA 77th Scientific Sessions
Patients who switched to insulin glargine 300 Units/mL were 57% less likely to experience hypoglycemia at 6-months.
Teens with Type 1 Diabetes Can Text Message Improved Glycemic Control
Teens with T1D improved their A1C levels by frequent 2-way texting.
Severely Obese Children Have Dangerously Increased Risk of Type 2 Diabetes
Severely obese American Indian children had a 12-times higher risk of developing T2D as normal-weight youth.
Overweight Boys Have Chance to Avoid Type 2 Diabetes
Boys who are overweight as children but normalize as young adults have the same risk of type 2 diabetes as men who were never overweight.
ADA 77th Scientific Sessions Packed with Clinical Trial Results
More than 3,000 original research presentations will be offered in a robust 5-day program.